All In Biotech

NDA 020641 · Bayer Healthcare LLC

Claritin Hives Relief

Loratadine · Oral

Last checked: Nov 19, 2026Latest source record: May 22, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Oct 10, 1996

Approved uses

4

Original approval plus efficacy supplements

Registered trials

89

27 Phase 3, 6 recruiting

FAERS reports

104,422

49,251 serious, 4,538 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 4, 2025.

Uses temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose itchy, watery eyes sneezing itching of the nose or throat

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 19, 2003 Supplement 11 · Efficacy Letter
  • Nov 27, 2002 Supplement 9 · Efficacy ReviewLetter
  • Dec 4, 2000 Supplement 7 · Efficacy LabelReviewLetter
  • Oct 10, 1996 Original approval · Type 3 - New Dosage Form
2 products under this application
  • CLARITIN HIVES RELIEF · LORATADINE 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SYRUP, ORAL · Discontinued
  • CLARITIN · LORATADINE 1MG/ML · SYRUP, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Loratadine" as an intervention, any sponsor and status, largest first.

All 89 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective12,282
  • fatigue6,606
  • nausea5,803
  • headache5,316
  • dyspnoea4,803
  • diarrhoea4,797
  • off label use4,595
  • dizziness4,298
  • pain4,057
  • rash3,383
  • pruritus3,361
  • cough3,106

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004965
20051,071
20061,067
2007939
20081,073
20091,316
20101,637
20112,020
20123,016
20133,961
20144,684
20157,326
20169,310
20178,781
20187,750
20197,823
20207,027
20216,322
20226,132
20235,526
20246,045
20255,986
20264,644

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 388 on PubMed

Sponsor: Bayer · Also marketed as Claritin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.